Physician profile
Danni L Eldred
NPI 1780214551
$3,750.92
in general payments reported to CMS, 2019-2025
46 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.22 · 2022: $501 · 2023: $1,262 · 2024: $862 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,865 · Education: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.73 |
| Education | $370.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $414.09 | 2022-2025 | Carvykti, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $243.66 | 2023-2025 | |
| Seagen INC. | $206.63 | 2023-2025 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $185.22 | 2022-2025 | Lynparza, Imfinzi |
| Pfizer INC. | $184.20 | 2021-2024 | |
| Genzyme Corporation | $170.96 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $170.00 | 2022-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $149.86 | 2023-2024 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $141.87 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $114.87 | 2023-2025 | Itovebi, Phesgo, Alecensa |
| Rigel Pharmaceuticals, INC. | $107.92 | 2022-2024 | Rezlidhia, Tavalisse |
| Glaxosmithkline, LLC. | $105.66 | 2025 | Ojjaara, Jemperli |
| Amgen INC. | $88.31 | 2022-2024 | Prolia, Evenity |
| Daiichi Sankyo INC. | $86.28 | 2024-2025 | Enhertu, Vanflyta, Injectafer |
| Sanofi-Aventis U.S. LLC | $83.00 | 2023 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $76.75 | 2023-2024 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $75.00 | 2022-2024 | Libtayo |
| Beigene USA, INC. | $67.94 | 2022-2025 | Brukinsa, Tevimbra |
| Telix Pharmaceuticals | $67.57 | 2024 | Illuccix |
| Genmab U.S., INC. | $58.30 | 2024 | Tivdak, Epkinly |
| Abbvie INC. | $56.67 | 2024 | |
| Pharmaessentia USA Corporation | $56.37 | 2023-2025 | Besremi |
| Alnylam Pharmaceuticals INC. | $53.29 | 2023-2025 | Givlaari |
| Eisai INC. | $53.08 | 2023-2025 | |
| Cti Biopharma Corp. | $52.69 | 2022-2023 | Vonjo |
| Merck Sharp & Dohme LLC | $51.99 | 2022-2024 | Lynparza, Keytruda |
| Alexion Pharmaceuticals, INC. | $51.10 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $50.48 | 2023-2025 | Trodelvy |
| Astellas Pharma US INC | $50.01 | 2025 | Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $49.55 | 2023-2025 | Fruzaqla, Iclusig |
| Sobi, INC | $49.16 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $42.60 | 2022-2024 | Onivyde |
| Emd Serono, INC. | $38.11 | 2023-2024 | Tepmetko |
| Sun Pharmaceutical Industries INC. | $37.65 | 2025 | |
| Monteris Medical Corporation | $31.28 | 2023 | Neuroblate |
| Sumitomo Pharma America, INC. | $25.26 | 2025 | Orgovyx |
| Coherus Oncology, INC. | $24.96 | 2023 | |
| Exelixis INC. | $23.56 | 2023 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $22.97 | 2024 | Provenge |
| Legend Biotech USA INC. | $22.67 | 2024 | |
| Blueprint Medicines Corporation | $22.28 | 2023 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $21.92 | 2025 | Qinlock, Romvimza |
| Pharmacosmos Therapeutics INC. | $17.33 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $17.27 | 2024 | Zoladex |
| Taiho Oncology, INC. | $16.23 | 2025 | |
| Adc Therapeutics America, INC. | $14.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danni Eldred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.